Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Vitzthum is a radiation oncologist and clinical associate professor of radiation oncology at Stanford University School of Medicine. He specializes in the treatment of gastrointestinal and thoracic cancers. He also has a clinical and research interest in oligometastatic cancer, which is cancer that has metastasized to a limited number of sites beyond its origin.
He began his career in biomedical engineering and is passionate about integrating new technologies to advance patient care.
Dr. Vitzthum delivers treatment personalized to each patient’s condition, overall health, and goals. He believes clear communication between doctor and patient is vital to help patients make informed care decisions.
His research interests include clinical trial development, survivorship, and predictive modeling to personalize patient treatment. He is especially interested in pursuing research that can address unmet clinical needs.
Dr. Vitzthum has received research support through the Radiological Society of North America, the American Society of Clinical Oncology’s Conquer Cancer Foundation, and the UCSD Altman Clinical and Translational Research Institute. His work has appeared in International Journal of Radiation Oncology Biology Physics, Annals of Oncology, JAMA Oncology, Clinical Cancer Research, and other publications.
He is a member of the American College of Radiation Oncology, American Society for Radiation Oncology, American Society of Clinical Oncology, and Radiologic Society of North America.
Dr. Vitzthum is also interested in improving access to high-quality cancer care for under-served populations domestically and abroad.
He began his career in biomedical engineering and is passionate about integrating new technologies to advance patient care.
Dr. Vitzthum delivers treatment personalized to each patient’s condition, overall health, and goals. He believes clear communication between doctor and patient is vital to help patients make informed care decisions.
His research interests include clinical trial development, survivorship, and predictive modeling to personalize patient treatment. He is especially interested in pursuing research that can address unmet clinical needs.
Dr. Vitzthum has received research support through the Radiological Society of North America, the American Society of Clinical Oncology’s Conquer Cancer Foundation, and the UCSD Altman Clinical and Translational Research Institute. His work has appeared in International Journal of Radiation Oncology Biology Physics, Annals of Oncology, JAMA Oncology, Clinical Cancer Research, and other publications.
He is a member of the American College of Radiation Oncology, American Society for Radiation Oncology, American Society of Clinical Oncology, and Radiologic Society of North America.
Dr. Vitzthum is also interested in improving access to high-quality cancer care for under-served populations domestically and abroad.
View Full Biography »
Professional Summary
Education & Certifications
- Medical Education: University of Minnesota School of Medicine (2015) MN
- Board Certification: American Board of Radiology, Radiation Oncology (2021)
- Residency: UCSD Radiation Oncology Residency Program (2020) CA
- Internship: Hennepin County Medical Center Transitional Year Residency (2016) MN
Honors & Awards
- Alpha Omega Alpha Medical Honor Society, University of Minnesota (2014)
- Dean's Merit Scholarship, University of Minnesota Medical School (2010-2015)
- Endowed Young Investigator Award, American Society of Clinical Oncology (2019)
- Resident Research Grant, RSNA (2019)
- Roentgen Research Award, RSNA (2020)
Publications
-
Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.
Mell, L. K., Shen, H., Nguyen-Tan, P. F., Rosenthal, D. I., Zakeri, K., Vitzthum, L. K., … Le, Q.-T. (2019). Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy
Vitzthum, L. K., Heide, E. S., Park, H., Williamson, C. W., Sheridan, P., Huynh-Le, M.-P., … Mell, L. K. (2020). Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy. FRONTIERS IN ONCOLOGY, 10, 1179. -
Managing Cancer Pain During the Opioid Epidemic-Balancing Caution and Compassion
Vitzthum, L. K., Riviere, P., & Murphy, J. D. (2020). Managing Cancer Pain During the Opioid Epidemic-Balancing Caution and Compassion. JAMA ONCOLOGY, 6(7), 1103–4. -
African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance
Deka, R., Parsons, J. K., Simpson, D. R., Riviere, P., Nalawade, V., Vitzthum, L. K., … Rose, B. S. (2020). African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. PROSTATE CANCER AND PROSTATIC DISEASES. -
Challenge of Directly Comparing Imaging-Based Diagnoses Made by Machine Learning Algorithms With Those Made by Human Clinicians
Simon, A. B., Vitzthum, L. K., & Mell, L. K. (2020). Challenge of Directly Comparing Imaging-Based Diagnoses Made by Machine Learning Algorithms With Those Made by Human Clinicians. JOURNAL OF CLINICAL ONCOLOGY, 38(16), 1868-+. -
Associations among statins, preventive care, and prostate cancer mortality
Kumar, A., Riviere, P., Luterstein, E., Nalawade, V., Vitzthum, L., Sarkar, R. R., … Rose, B. S. (2020). Associations among statins, preventive care, and prostate cancer mortality. PROSTATE CANCER AND PROSTATIC DISEASES, 23(3), 475–85. -
Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy
Vitzthum, L. K., Straka, C., Sarkar, R. R., Mckay, R., Randall, J. M., Sandhu, A., … Rose, B. S. (2019). Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(12), 1497-+. -
Predicting Persistent Opioid Use, Abuse, and Toxicity Among Cancer Survivors.
Vitzthum, L. K., Riviere, P., Sheridan, P., Nalawade, V., Deka, R., Furnish, T., … Murphy, J. D. (2020). Predicting Persistent Opioid Use, Abuse, and Toxicity Among Cancer Survivors. Journal of the National Cancer Institute, 112(7), 720–27. -
Reducing prolonged chemoradiation treatment times for cervical cancer.
Vitzthum, L., Yuan, J., Jones, D., Boldt, A., & Dusenbery, K. (2019). Reducing prolonged chemoradiation treatment times for cervical cancer. BMJ Open Quality, 8(3), e000516. -
Tobacco smoking and death from prostate cancer in US veterans
Riviere, P., Kumar, A., Luterstein, E., Vitzthum, L. K., Nalawade, V., Sarkar, R. R., … Rose, B. S. (2020). Tobacco smoking and death from prostate cancer in US veterans. PROSTATE CANCER AND PROSTATIC DISEASES, 23(2), 252–59. -
Risk of Pelvic Fracture With Radiation Therapy in Older Patients
Vitzthum, L. K., Park, H., Zakeri, K., Heide, E. S., Nalawade, V., Mundt, A. J., … Mell, L. K. (2020). Risk of Pelvic Fracture With Radiation Therapy in Older Patients. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 106(3), 485–92. -
Selection of Head and Neck Cancer Patients for Intensive Therapy
Vitzthum, L. K., Park, H., Zakeri, K., Bryant, A. K., Feng, C., Shen, H., … Mell, L. K. (2020). Selection of Head and Neck Cancer Patients for Intensive Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 106(1), 157–66. -
Generalized Competing Event Models Can Reduce Cost and Duration of Cancer Clinical Trials
Zakeri, K., Panjwani, N., Carmona, R., Shen, H., Vitzthum, L. K., Zhang, Q. E., … Mell, L. K. (2018). Generalized Competing Event Models Can Reduce Cost and Duration of Cancer Clinical Trials. JCO CLINICAL CANCER INFORMATICS, 2, 1–12. -
Comparison of Comorbidity and Frailty Indices in Patients With Head and Neck Cancer Using an Online Tool
Vitzthum, L. K., Feng, C. H., Noticewala, S., Hines, P. J., Nguyen, C., Zakeri, K., … Mell, L. K. (2018). Comparison of Comorbidity and Frailty Indices in Patients With Head and Neck Cancer Using an Online Tool. JCO CLINICAL CANCER INFORMATICS, 2, 1–9. -
Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer
Bryant, A. K., Sojourner, E. J., Vitzthum, L. K., Zakeri, K., Shen, H., Nguyen, C., … Mell, L. K. (2018). Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(12), 1393–99. -
Optimism bias' in contemporary national clinical trial network phase III trials: are we improving?
Zakeri, K., Noticewala, S. S., Vitzthum, L. K., Sojourner, E., Shen, H., & Mell, L. K. (2018). Optimism bias' in contemporary national clinical trial network phase III trials: are we improving? ANNALS OF ONCOLOGY, 29(10), 2135–39. -
The role of p16 as a biomarker in nonoropharyngeal head and neck cancer.
Vitzthum, L. K., & Mell, L. K. (2018). The role of p16 as a biomarker in nonoropharyngeal head and neck cancer. Oncotarget, 9(70), 33247–48. -
Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system.
Riviere, P., Luterstein, E., Kumar, A., Vitzthum, L. K., Deka, R., Sarkar, R. R., … Rose, B. S. (2020). Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer, 126(8), 1683–1690. -
Head and Neck Soft Tissue Sarcomas Treated with Radiation Therapy.
Vitzthum, L. K., Brown, L. C., Rooney, J. W., & Foote, R. L. (2016). Head and Neck Soft Tissue Sarcomas Treated with Radiation Therapy. Rare Tumors, 8(2), 6165. -
Study of Na+/H+ exchange-mediated pHi regulations in neuronal soma and neurites in compartmentalized microfluidic devices.
Vitzthum, L., Chen, X., Kintner, D. B., Huang, Y., Chiu, S.-Y. Y., Williams, J., & Sun, D. (2010). Study of Na+/H+ exchange-mediated pHi regulations in neuronal soma and neurites in compartmentalized microfluidic devices. Integrative Biology : Quantitative Biosciences from Nano to Macro, 2(1), 58–64. -
Global engineering education initiative through student organization.
Sagstetter, A. M., Vitzthum, L. K., Meyer, J. R., Nimunkar, A. J., & Webster, J. G. (2009). Global engineering education initiative through student organization. Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference, 2009, 2022–4. -
Cost-effectiveness Analysis of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Cancer.
Kumar, A., Straka, C., Courtney, P. T., Vitzthum, L., Riviere, P., & Murphy, J. D. (2020). Cost-effectiveness Analysis of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Cancer. International Journal of Radiation Oncology, Biology, Physics. -
Predictive classifier for intensive treatment of head and neck cancer.
Zakeri, K., Rotolo, F., Lacas, B., Vitzthum, L. K., Le, Q.-T. T., Gregoire, V., … Mell, L. K. (2020). Predictive classifier for intensive treatment of head and neck cancer. Cancer. -
Validation of an oncology-specific opioid risk calculator in cancer survivors.
Riviere, P., Vitzthum, L. K., Nalawade, V., Deka, R., Furnish, T., Mell, L. K., … Murphy, J. D. (2020). Validation of an oncology-specific opioid risk calculator in cancer survivors. Cancer. -
Microstructural injury to corpus callosum and intra-hemispheric white matter tracts correlate with attention and processing speed decline after brain radiation.
Huynh-Le, M.-P. P., Tibbs, M. D., Karunamuni, R., Tringale, K. R., Salans, M., Yip, A., … Hattangadi-Gluth, J. A. (2021). Microstructural injury to corpus callosum and intra-hemispheric white matter tracts correlate with attention and processing speed decline after brain radiation. International Journal of Radiation Oncology, Biology, Physics. -
Racial, Ethnic, and Socioeconomic Discrepancies in Opioid Prescriptions Among Older Patients With Cancer.
Vitzthum, L. K., Nalawade, V., Riviere, P., Sumner, W., Nelson, T., Mell, L. K., … Murphy, J. D. (2021). Racial, Ethnic, and Socioeconomic Discrepancies in Opioid Prescriptions Among Older Patients With Cancer. JCO Oncology Practice, OP2000773. -
Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines.
Vitzthum, L. K., Hui, C., Pollom, E. L., & Chang, D. T. (2021). Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines. Practical Radiation Oncology. -
Pancreatic Stereotactic Body Radiation Therapy with or without Hypofractionated Elective Nodal Irradiation.
Miller, J. A., Toesca, D. A., Baclay, J. R., Vitzthum, L. K., Dubrowski, P., Pollom, E. L., & Chang, D. T. (2021). Pancreatic Stereotactic Body Radiation Therapy with or without Hypofractionated Elective Nodal Irradiation. International Journal of Radiation Oncology, Biology, Physics. -
End of treatment cone-beam computed tomography (CBCT) is predictive of radiation response and overall survival in oropharyngeal squamous cell carcinoma.
Sumner, W., Kim, S. S., Vitzthum, L., Moore, K., Atwood, T., Murphy, J., … Sharabi, A. B. (2021). End of treatment cone-beam computed tomography (CBCT) is predictive of radiation response and overall survival in oropharyngeal squamous cell carcinoma. Radiation Oncology (London, England), 16(1), 147. -
Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients.
Qiao, E. M., Voora, R. S., Nalawade, V., Kotha, N. V., Qian, A. S., Nelson, T. J., … Rose, B. S. (2021). Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients. Cancer Medicine. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Treatment Patterns for Isolated Nodal Recurrences in Non-Small Cell Lung Cancer After Definitive Stereotactic Ablative Radiotherapy
No, H., Devine, M., Lau, B., Loo, B., Diehn, M., Chin, A., & Vitzthum, L. (2021). Treatment Patterns for Isolated Nodal Recurrences in Non-Small Cell Lung Cancer After Definitive Stereotactic Ablative Radiotherapy. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
IMRT Treatment Planning Study for the First Clinical Biology-guided Radiotherapy System
Kovalchuk, N., Pham, D., Breitkreutz, D., Simiele, E., Capaldi, D., Vitzthum, L., & Chang, D. (2021). IMRT Treatment Planning Study for the First Clinical Biology-guided Radiotherapy System. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Impact of the VA opioid safety initiative on pain management for cancer patients.
Marar, M., Nalawade, V., Panjwani, N., Riviere, P., Furnish, T., Lin, L. A., … Vitzthum, L. K. (2021). Impact of the VA opioid safety initiative on pain management for cancer patients. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Temporal Trends and Predictors of Opioid Use Among Older Patients With Cancer.
Salans, M., Riviere, P., Vitzthum, L. K., Nalawade, V., & Murphy, J. D. (1800). Temporal Trends and Predictors of Opioid Use Among Older Patients With Cancer. American Journal of Clinical Oncology. -
Progression Versus Radiation Treatment Changes After Stereotactic Ablative Radiation Therapy of a Liver Metastasis
No, H. J., Negrete, L. M., Pollom, E. L., Wakelee, H. A., Chang, D. T., & Vitzthum, L. K. (2022). Progression Versus Radiation Treatment Changes After Stereotactic Ablative Radiation Therapy of a Liver Metastasis. PRACTICAL RADIATION ONCOLOGY, 12(1), 1–2. -
Impacts of an Opioid Safety Initiative on United States Veterans Undergoing Cancer Treatment.
Vitzthum, L. K., Nalawade, V., Riviere, P., Marar, M., Furnish, T., Lin, L. A., … Murphy, J. D. (2022). Impacts of an Opioid Safety Initiative on United States Veterans Undergoing Cancer Treatment. Journal of the National Cancer Institute. -
Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data.
Williamson, C. W., Nelson, T., Thompson, C. A., Vitzthum, L. K., Zakeri, K., Riviere, P., … Mell, L. K. (2022). Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Jumping to conclusions: Misdiagnosing radiation induced sarcoma as recurrent breast cancer.
Chughtai, K., Negrete, L., & Vitzthum, L. K. (2022). Jumping to conclusions: Misdiagnosing radiation induced sarcoma as recurrent breast cancer. Clinical Imaging, 84, 110–112. -
Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database.
Nelson, T. J., Thompson, C. A., Zou, J., Kumar, A., Sangchan, P., Williamson, C. W., … Mell, L. K. (2022). Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database. Cancer. -
Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX)
Pollom, E. L., Shelton, A., Fisher, G. A., Bien, J., King, D., Johnson, T. P., … Chang, D. T. (2022). Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System.
Pham, D., Simiele, E., Breitkreutz, D., Capaldi, D., Han, B., Surucu, M., … Kovalchuk, N. (2022). IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System. Technology in Cancer Research & Treatment, 21, 15330338221100231. -
Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics. -
Evaluating High-Dimensional Machine Learning Models to Predict Hospital Mortality Among Older Patients With Cancer.
Qiao, E. M., Qian, A. S., Nalawade, V., Voora, R. S., Kotha, N. V., Vitzthum, L. K., & Murphy, J. D. (2022). Evaluating High-Dimensional Machine Learning Models to Predict Hospital Mortality Among Older Patients With Cancer. JCO Clinical Cancer Informatics, 6, e2100186. -
Neoadjuvant therapy in the post-German rectal trial era: making sense in the absence of consensus.
Hui, C., Vitzthum, L. K., Chang, D. T., & Pollom, E. L. (2022). Neoadjuvant therapy in the post-German rectal trial era: making sense in the absence of consensus. Practical Radiation Oncology. -
Rectosigmoid Cancer-Rectal Cancer or Sigmoid Cancer?
Hui, C., Baclay, R., Liu, K., Sandhu, N., Loo, P., von Eyben, R., … Pollom, E. (2022). Rectosigmoid Cancer-Rectal Cancer or Sigmoid Cancer? American Journal of Clinical Oncology. -
Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., … Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology. -
Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer
Hui, C., Marquez, C., Lau, B., Von Eyben, R., Das, M., Myall, N., … Vitzthum, L. (2022). Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR)
Wu, Y. F., Lau, B., Fu, J., Skinner, L., Gensheimer, M., Gee, H., … Vitzthum, L. (2022). Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR). AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Image-mode performance characterization of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT).
Hu, Z., Bieniosek, M., Ferri, V., Iagaru, A., Kovalchuk, N., Han, B., … Surucu, M. (2022). Image-mode performance characterization of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT). The British Journal of Radiology, 20220387. -
Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series.
Nief, C. A., No, H. J., Louie, C. Y., Vitzthum, L., & Das, M. (2022). Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series. Clinical Lung Cancer. -
Quantitative prediction of aspiration risk in head and neck cancer patients treated with radiation therapy.
Liu, H. C., Williamson, C. W., Zou, J., Todd, J. R., Nelson, T. J., Hill, L. M., … Mell, L. K. (2022). Quantitative prediction of aspiration risk in head and neck cancer patients treated with radiation therapy. Oral Oncology, 136, 106247. -
Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wong, L.-Y., Liou, D. Z., Vitzthum, L. K., Backhus, L. M., Lui, N. S., Chang, D., … Berry, M. F. (2022). Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology. -
Mitigation of IMRT/SBRT treatment planning errors on the RefleXion X1 system using FMEA within Six Sigma framework
Simiele, E., Han, B., Skinner, L., Pham, D., Lewis, J., Gensheimer, M., … Kovalchuk, N. (2023). Mitigation of IMRT/SBRT treatment planning errors on the RefleXion X1 system using FMEA within Six Sigma framework. Advances in Radiation Oncology. -
ASO Visual Abstract: Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wong, L.-Y. Y., Liou, D. Z., Vitzthum, L. K., Backhus, L. M., Lui, N. S., Chang, D., … Berry, M. F. (2023). ASO Visual Abstract: Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology. -
Outcomes and Imaging Analysis in Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy.
Hui, C., Baclay, R., Lau, B., von Eyben, R., Vitzthum, L., Pollom, E., & Chang, D. T. (2023). Outcomes and Imaging Analysis in Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Practical Radiation Oncology, 13(2), e139–e148. -
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.
Taïeb, D., Wanna, G. B., Ahmad, M., Lussey-Lepoutre, C., Perrier, N. D., Nölting, S., … Pacak, K. (2023). Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. The Lancet. Diabetes & Endocrinology. -
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., … Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., … Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Unilateral diaphragmatic paralysis after stereotactic ablative radiotherapy to a lung tumor abutting the course of the phrenic nerve.
Eke, I., Guo, H. H., Loo, J. B., Sung, A. W., Diehn, M., Vitzthum, L., … Gensheimer, M. F. (2023). Unilateral diaphragmatic paralysis after stereotactic ablative radiotherapy to a lung tumor abutting the course of the phrenic nerve. Practical Radiation Oncology. -
Diverging Roads in the Management of Metastatic EGFR Mutated Non Small Cell Lung Cancer: Ablate All, None, or Some?
Vitzthum, L. K., & Pollom, E. L. (2023). Diverging Roads in the Management of Metastatic EGFR Mutated Non Small Cell Lung Cancer: Ablate All, None, or Some? International Journal of Radiation Oncology, Biology, Physics, 116(3), 479–480. -
Adaptive Region-Specific Loss for Improved Medical Image Segmentation.
Chen, Y., Yu, L., Wang, J.-Y., Panjwani, N., Obeid, J.-P., Liu, W., … Xing, L. (2023). Adaptive Region-Specific Loss for Improved Medical Image Segmentation. IEEE Transactions on Pattern Analysis and Machine Intelligence, PP. -
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., … Diehn, M. (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology. -
Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultsides, G., … Vitzthum, L. K. (2023). Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. Annals of Surgical Oncology. -
ASO Author Reflections: A Role for Neoadjuvant Radiation in the Treatment of Locally Advanced Gastric Cancer?
Hui, C., & Vitzthum, L. K. (2023). ASO Author Reflections: A Role for Neoadjuvant Radiation in the Treatment of Locally Advanced Gastric Cancer? Annals of Surgical Oncology. -
ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultsides, G., … Vitzthum, L. K. (2023). ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. Annals of Surgical Oncology. -
Volumetric MRI with sparse sampling for MR-guided 3D motion tracking via sparse prior-augmented implicit neural representation learning.
Liu, L., Shen, L., Johansson, A., Balter, J. M., Cao, Y., Vitzthum, L., & Xing, L. (2023). Volumetric MRI with sparse sampling for MR-guided 3D motion tracking via sparse prior-augmented implicit neural representation learning. Medical Physics. -
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. -
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., … Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer. -
BIOGUIDE-X: A First-in-Human Study of the Performance of Positron Emission Tomography-Guided Radiotherapy.
Vitzthum, L. K., Surucu, M., Gensheimer, M. F., Kovalchuk, N., Han, B., Pham, D., … Garant, A. (2023). BIOGUIDE-X: A First-in-Human Study of the Performance of Positron Emission Tomography-Guided Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. -
Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
No, H. J., Guo, F. B., Park, N. J.-I., Kastelowitz, N., Rhee, J.-W. W., Clark, D. E., … Binkley, M. S. (2023). Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. JACC. CardioOncology, 5(6), 775–787. -
Risk of developing subsequent primary lung cancer after receiving radiation for breast cancer.
Wong, L.-Y., Kapula, N., He, H., Guenthart, B. A., Vitzthum, L. K., Horst, K., … Elliott, I. A. (2023). Risk of developing subsequent primary lung cancer after receiving radiation for breast cancer. JTCVS Open, 16, 919–928. -
First-Year Experience of Stereotactic Body Radiation Therapy/Intensity Modulated Radiation Therapy Treatment Using a Novel Biology-Guided Radiation Therapy Machine.
Shi, M., Simiele, E., Han, B., Pham, D., Palomares, P., Aguirre, M., … Kovalchuk, N. (2024). First-Year Experience of Stereotactic Body Radiation Therapy/Intensity Modulated Radiation Therapy Treatment Using a Novel Biology-Guided Radiation Therapy Machine. Advances in Radiation Oncology, 9(1), 101300. -
Lung Cancer Survival Trends in the Veterans Health Administration.
Moghanaki, D., Taylor, J., Bryant, A. K., Vitzthum, L. K., Sebastian, N., Gutman, D., … Stokes, W. A. (2024). Lung Cancer Survival Trends in the Veterans Health Administration. Clinical Lung Cancer.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Radiation Oncology at Blake Wilbur Building Palo Alto, CA
Palo Alto, CA
Radiation Oncology at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur Palo Alto, CA
Palo Alto, CA
CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Thoracic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Thoracic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Gastrointestinal (GI) Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Gastrointestinal (GI) Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Endocrine Tumor Program - 875 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Endocrine Tumor Program - 875 Blake Wilbur Drive
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(61 reviews)
Dr Vitzthum was extremely helpful in explaining the treatment proposed for me. He gave me confidence that I will benefit greatly from radiation therapy. He was also very reassuring in explaining side effects. He is also aided by a great team. I look forward to working with them in the future.
Seems genuinely concerned with helping me.
Dr. Vitzthum is an awesome doctor and extremely professional and kind.Thank you!
Always a pleasure to speak with the doctor. He is very friendly, approachable, and ask very appropriate questions to my situation. He even asked me how I was feeling today, which I thank him for that.
Good doctor
Very nice Doctor
Dr. Vitzthum is always professional.
I am fortunate to have him and staff.
He was very straightforward and answered all my questions.
Extremely helpful.
I am so blessed that Dr. Vitzthum is my radiation Doctor.
I value the doctors advice, and his knowledge. It is extremely easy to speak with him about how I feel and where I go from here. He is an excellent doctor and I appreciate all his efforts and service.
Seems very supportive
I am so happy to have met Dr. Vitzthum.
I feel comfortable with the information he gave me. I’m very fortunate to have him on my side
He’s a great Doctor. Always answers questions and provides plenty information as far as treatment goes.
outstandind
The call was very productive. All my questions were answered.
Dr, Vitzthum is very thorough and has been wonderful throughout our meetings with him.
Very professional
I had a couple of delays on my part and the doctor was patient with me.
A good visit with very positive results from the last MRI that dealt with spots on my liver that were burned up during three radiation treatments.
Dr. Vitzthum was very clear, direct, and engaging. He followed up on my questions. I appreciated his time!
I love his spirit of camaraderie.
Easy to talk to, informative.
Doctor Vitzthum’s patient Interaction skills are excellent.
Met with knowledgable personnel - from the nurses up! It is almost a pleasure. It relieved me from the veritable worries about my health given such keen and supportive staff!
Seemed knowledgeable and was open to discussion.
Dr Vitzthum was amazing and highly professional. He was so detailed and providing excellent information and gave us an extreme level of confidence. His kindness and hopefulness came though on the video call clearly. Susie his nurse was equally as excellent and truly kind. We loved our visit on a challenging topic with many treatments for complete healing. So grateful for their time and care.
Dr. Vitzthum was easy to talk to, answered all my questions, and gave me hope. For someone recently diagnosed with stage 4 cancer, this makes a huge difference in my life. I appreciate his help.
Dr. Vitzthum is considerate and thorough. He knows my physical needs and makes sure I give him feedback.
He is amazing. He is very knowledgeable and very articulate. He explained everything methodically and answered all my questions and concerns. He is a gem.
Thank you for having such a wonderful doctor at Stanford.
world class operation, very attentive to patient. well done.
Very helpful
clear & concise
Explained everything in detail.
Very informative, great summary letter
Very professional
Dr. Vitzthum is amazing! He always listens, interacts in a way that I can understand. He is knowledgeable and caring.
I would recommend Dr. Vitzthum!
I think he's great!
Dr Vitzthum is great. He is informative and pleasant to talk to. I don't feel intimidated by him which is nice, it makes me want to ask him questions which is important to my health.
Dr. Lucas is a good doctor. He cares to his patients as his family member. I am appreciated his time, advices and team work.
I really appreciate your honest approach and ease with which you explained things. Thank you all!
Very Knowlegable and helpful
I appreciate that I was "prepped for the phone calls and the Dr Was very clear on explanations.
Extremely profesional and showed a lot of knowledge and human kindness
This was the first time I met Dr. Vitzthum and I liked him; the video conference was effective enough to make me feel like we had established a good relationship.
Very clear about problems, answered all questions
very personable and answered all questions and gave very complete information as what to expect from radiation therapy.
Dr. Vitzthum was very helpful. He answered all of my questions and went into great detail in a way that was concise and understandable.
Very personable.
Nice man, easy to understand
I appreciate Dr. Vitzthum answering all my questions(without rushing me to finish). Also he spoke in language that I can understand without speaking down to me.
Very helpful and knowledgeable.
Doctor Lucas is a good doctor. His knowledge and explanation bring me up with respectfully
Outstanding. Stanford and staff were amazingly Outstanding.
Excellent team and supportive resource
Was good
Dr Vitzthum is excellent, kind, caring, supportive, and compassionate
Outstanding!
Excellent doctor....he explains every thing I ask which helps me navigate my condition.
Excellent doctor, willing to answer any questions
Great Doctor. Very competent and gracious.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records